[artículo] 
inThe British Journal of Psychiatry > Año 2021 - Vol. 219 - No. 5 (Noviembre) . - pp. 614 - 617

Título :	Are we repeating mistakes of the past? A review of the evidence for esketamine
Tipo de documento:	texto impreso
Autores:	Mark A. Horowitz, Autor ; Joanna Moncrieff, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 614 - 617
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Esketamina, Ketamina, Depresión, Antidepresivos, Suicidio
Resumen:	Esketamine has been licensed for ‘treatment-resistant depression’ in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent.
Link:	./index.php?lvl=notice_display&id=28500

[artículo] Are we repeating mistakes of the past? A review of the evidence for esketamine [texto impreso] / Mark A. Horowitz, Autor ; Joanna Moncrieff, Autor . - 2022 . - pp. 614 - 617.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The British Journal of Psychiatry > Año 2021 - Vol. 219 - No. 5 (Noviembre) . - pp. 614 - 617

Palabras clave:	Esketamina, Ketamina, Depresión, Antidepresivos, Suicidio
Resumen:	Esketamine has been licensed for ‘treatment-resistant depression’ in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent.
Link:	./index.php?lvl=notice_display&id=28500